Client News

Axxam and HeartBeat.bio partner to advance human-relevant cardiovascular drug discovery and cardiac safety assessment

Abivax Announces Closing of $920 Million Public Offering

AFYREN announces the resumption of production at its plant after the successful technical shutdown

REPRONOVO ANNOUNCES FIRST PARTICIPANT DOSED IN EU PHASE 2 TRIAL OF RPN-002 FOR EMBRYO IMPLANTATION

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

Rentschler Biopharma appoints Dr. Torsten Woehr as Chief Executive Officer

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Mallia Innovations Secures €3 Million Financing to Accelerate Commercial Expansion of the 8T3 Essentials Line

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris